Blueprint Medicines Stock News

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ: BPMC ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0 Last 30D 1 0 1 0 0 1M Ago 1 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Blueprint Medicines. The company has an average price target of $97.8 with a high of $120.00 and a low of $82.00. Below is a summary of … Full story available on Benzinga.com

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Blueprint Medicines <> is trading sharply lower in the morning hours on Wednesday after the company initiated a lower-than-expected revenue guidance for 2022

Shares of Blueprint Medicines Corporation (BPMC) are falling more than 9% Wednesday morning after the company reported wider loss for the fourth-quarter that missed the Street view. The company''s full-year revenue outlook also came in below consensus estimates.

Blueprint Medicines' (BPMC) CEO Jeff Albers on Q4 2021 Results - Earnings Call Transcript

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

Blueprint Medicines press release (BPMC): Q4 GAAP EPS of -$5.40 misses by $4.25.Revenue of $107M (+213.7% Y/Y) beats by $2.86M.Blueprint Medicines today announced it…

CAMBRIDGE, Mass., Feb. 16, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2021. "Following a year of outstanding execution across our portfolio, we…

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q4 earnings on Wednesday, Feb. 16, before market open.The consensus EPS estimate is -$1.57

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

CAMBRIDGE, Mass., Feb. 11, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences. SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 10:40 a.m. ET. Cowen 42nd…